Investigational drug · Phase 2
HM15136
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Congenital Hyperinsulinism.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "HM15136"
First trial start
2022
May 5, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HM15136", any sponsor or status.
Conditions studied
As listed on its trial records.
- Congenital Hyperinsulinism
Approved drugs for the same conditions: Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "HM15136" as an intervention, largest first.
Hanmi Pharmaceutical Company LimitedIndustry
NCT04167553 · 52 participants · Start Aug 30, 2019 · Primary completion Dec 9, 2020
Drug: HM15136; Placebo · For: Obese With Comorbidities; Overweight With Comorbidities; Type2 Diabetes
Sites: San Diego, California
Hanmi Pharmaceutical Company LimitedIndustry
NCT04032782 · 40 participants · Start Oct 2, 2018 · Primary completion Aug 29, 2019
Drug: HM15136; Placebo of HM15136 · For: Pharmacology
Sites: Seoul, South Korea
- HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)Active, not recruiting
Hanmi Pharmaceutical Company LimitedIndustry
NCT04732416 · 17 participants · Start May 5, 2022 · Primary completion Jun 16, 2026
Drug: HM15136 · For: Congenital Hyperinsulinism
Sites: Philadelphia, Pennsylvania; Magdeburg, Germany; Jerusalem, Israel · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of the novel long-acting glucagon analogue HM15136 in overweight and obese patients with co-morbidities.
Shin W, Hompesch M, Byeon J, et al. · Diabetes Obes Metab 2023
- A novel glucagon analog with an extended half-life, HM15136, normalizes glucose levels in rodent models of congenital hyperinsulinism.
Heo YH, Kim JK, Lee JS, et al. · Sci Rep 2022
- A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects.
Huh KY, Hwang JG, Shin W, et al. · Diabetes Obes Metab 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.